KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Accured Expenses (2016 - 2026)

Alnylam Pharmaceuticals filings provide 18 years of Change in Accured Expenses readings, the most recent being -$176.0 million for Q1 2026.

  • Quarterly Change in Accured Expenses fell 11.6% to -$176.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $56.8 million through Mar 2026, up 191.89% year-over-year, with the annual reading at $75.1 million for FY2025, 17.59% down from the prior year.
  • Change in Accured Expenses hit -$176.0 million in Q1 2026 for Alnylam Pharmaceuticals, down from -$174.9 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $223.5 million in Q3 2025 and bottomed at -$176.0 million in Q1 2026.
  • Average Change in Accured Expenses over 5 years is $15.5 million, with a median of $68.1 million recorded in 2022.
  • Peak annual rise in Change in Accured Expenses hit 167.37% in 2025, while the deepest fall reached 3142.24% in 2025.
  • Alnylam Pharmaceuticals' Change in Accured Expenses stood at $102.6 million in 2022, then crashed by 137.68% to -$38.7 million in 2023, then tumbled by 60.62% to -$62.1 million in 2024, then tumbled by 181.54% to -$174.9 million in 2025, then fell by 0.67% to -$176.0 million in 2026.
  • Per Business Quant, the three most recent readings for ALNY's Change in Accured Expenses are -$176.0 million (Q1 2026), -$174.9 million (Q4 2025), and $223.5 million (Q3 2025).